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Serotonin (5-HT) and its receptors play crucial roles in various aspects of mood and
cognitive functions. However, the role of specific 5-HT receptors in these processes
remains to be better understood. Here, we examined the effects of the selective
and potent 5-HT6 agonist (WAY208466) on mood, anxiety and emotional learning
in mice. Male C57Bl/6J mice were therefore tested in the forced swim test (FST),
elevated plus-maze (EPM), and passive avoidance tests (PA), respectively. In a dose-
response experiment, mice were treated intraperitoneally with WAY208466 at 3, 9, or
27 mg/kg and examined in an open field arena open field test (OFT) followed by the
FST. 9 mg/kg of WAY208466 reduced immobility in the FST, without impairing the
locomotion. Thus, the dose of 9 mg/kg was subsequently used for tests of anxiety
and emotional learning. There was no significant effect of WAY208466 in the EPM. In
the PA, mice were trained 30 min before the treatment with saline or WAY208466. Two
separate sets of animals were used for short term memory (tested 1 h post-training)
or long term memory (tested 24 h post-training). WAY208466 improved both short and
long term memories, evaluated by the latency to enter the dark compartment, in the
PA. The WAY208466-treated animals also showed more grooming and rearing in the
light compartment. To better understand the molecular mechanisms and brain regions
involved in the facilitation of emotional learning by WAY208466, we studied its effects
on signal transduction and immediate early gene expression. WAY208466 increased
the levels of phospho-Ser845-GluA1 and phospho-Ser217/221-MEK in the caudate-
putamen. Levels of phospho-Thr202/204-Erk1/2 and the ratio mature BDNF/proBDNF
were increased in the hippocampus. Moreover, WAY208466 increased c-fos in the
hippocampus and Arc expression in both hippocampus and prefrontal cortex (PFC). The
results indicate antidepressant efficacy and facilitation of emotional learning by 5-HT6
receptor agonism via mechanisms that promote neuronal plasticity in caudate putamen,
hippocampus, and PFC.
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Introduction
Brain serotonin (5-HT) is implicated in a wide variety of physiological functions related to mood,
cognition and movements. The mechanisms whereby 5-HT6 and its receptors exert its versatile
functions are complex and often contradictory. For example, 5-HT6 agonists (Svenningsson et al.,
2007; Carr et al., 2011; Kendall et al., 2011) and antagonists (Hirst et al., 2006; Wesolowska and
Nikiforuk, 2007, 2008; Hirano et al., 2009) have procognitive and/or antidepressant-like eﬀects in
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animal models. Nonetheless, since many serotonergic
compounds have entered, or are about to enter, the clinics,
it is critically important to better delineate action of serotonergic
compounds. This is particularly evident for 5-HT6 ligands as the
combination of donepezil with a 5-HT6 antagonist, idalopirdine,
improved the cognitive function of patients with Alzheimer’s
Disease (Wilkinson et al., 2014).
The exact role of 5-HT6 receptor activation for memory
acquisition and consolidation is not yet completely understood.
Virally mediated gene transfer to overexpress 5-HT6 receptors
in the striatum had no eﬀect on performance in the Morris
water maze (hippocampus-dependent), but impaired the
acquisition of a reward-based instrumental learning task
(striatum-dependent), an eﬀect rescued by treatment with
the 5-HT6 antagonist, SB-258585 (Mitchell et al., 2007).
However, treatment with the 5-HT6 agonist, WAY181187,
facilitated extra-dimensional attentional set shifting [prefrontal
cortex (PFC)-dependent] and increased c-fos expression
in the PFC (Burnham et al., 2010). Administration of
the 5-HT6 agonists, E-6801, or EMD-386088, reversed
the cognitive deﬁcits induced by scopolamine or MK-801
pretreatment in the conditioned emotion response, a cued
and contextual fear memory (hippocampal, amygdala, and
cortical-dependent; Woods et al., 2012). Paradoxically, both
administration E-6801 and EMD-386088 as well as the 5-
HT6 antagonists, SB-271046 and Ro 04–6790, improved the
recognition memory (hippocampal-dependent; Kendall et al.,
2011).
The PA test evaluates emotional memory (Burwell et al.,
2004; Mitchell and Neumaier, 2005; Eriksson et al., 2008). PA
is considered a complex memory test since it is comprised by
both a Pavlovian component and also requires an instrumental
response. In this test, animals are required to suppress the natural
preference of a dark compartment to avoid a foot shock (e.g.,
Baamonde et al., 1992; Ogren et al., 2008). PA is hippocampal
dependent and several studies have shown the importance of
serotonin in this test (Misane and Ogren, 2000; Eriksson et al.,
2008, 2013). The role of 5-HT6 agonists in PA is unknown, but
other hippocampal dependent memories are modulated by 5-
HT6 agonists (Kendall et al., 2011; Woods et al., 2012) and 5-HT6
antagonists (Lieben et al., 2005; Meneses et al., 2007; Kendall
et al., 2011; Woods et al., 2012).
We have previously shown that the 5-HT6 agonist 2-
ethyl-5-methoxy-N,N-dimethyltryptamine (EMDT), similarly to
ﬂuoxetine, induces antidepressant eﬀect in the mouse tail
suspension test and increases the phospho-Ser845-GluA1 subunit
of the AMPA receptor in the PFC and striatum (Svenningsson
et al., 2007). Interestingly, the 5-HT6 antagonist, SB271046,
blocked not only the eﬀects of EMDT and but also counteracted
eﬀects of ﬂuoxetine (Svenningsson et al., 2007).
The objective of this study was to further evaluate emotional
processing along with antidepressant and anxiolytic actions by
the highly selective and potent 5-HT6 agonist, WAY208466
(Schechter et al., 2008). Moreover, to understand molecular
mechanisms of action and brain regions engaged byWAY208466,
we also evaluated its eﬀects on signal transduction and immediate
early genes (IEGs) involved in neuronal plasticity. The roles
of many IEGs are indeed related to neuroplasticity (Pei
et al., 2004). Here we studied representative genes from two
classes, a transcription factor (i.e., c-fos) and an eﬀector (i.e.,




Adult male C57Bl/6J mice were obtained from Janvier labs
(Scand-las Turku, Finland) and housed under controlled
temperature and humidity with food and water ad libitum
and in a 12 h light/dark controlled cycle. All experiments
were carried out in agreement with the European Council
Directive (86/609/EEC) and were approved by the local Animal
Ethics Committee (N40/13; Stockholm Norra Djurförsöksetiska
Nämnd). All eﬀorts were made to reduce the number of animals
used and to minimize their suﬀering.
Treatment
For all behavioral testing, animals were brought to the
experimental room 30 min for habituation. Animals then
received a single intraperitoneal injection of WAY208466
(3-[(-3-Fluorophenyl)sulfonyl]-N,N-dimethyl-1H-pyrrolo[2,3-
b]pyridine-1-ethanamine dihydrochloride; Tocris Bioscience,
Bristol, UK) or vehicle (saline) 30 min prior to behavioral tests. In
an initial dose-response experiment, we examined three diﬀerent
doses (3, 9, and 27 mg/kg) of WAY208466 in the OFT and in the
FST. Since the dose of 27 mg/kg impaired locomotor activity in
the OFT and the dose of 3 mg/kg did not reduce the immobility
in the FST, we used 9 mg/kg for subsequent tests (i.e., PA and
EPM). In addition, and for comparison, naïve groups were
treated with vehicle or 9 mg/kg of WAY208466 and euthanized.
Behavioral Tests
Forced Swim Test
The Porsolt forced swim test (FST) procedure was performed as
described earlier (Cervo et al., 2005). Animals were individually
placed in a vertical Plexiglas cylinder (height: 30 cm, diameter:
20 cm) ﬁlled with 15 cm depth water at 23–25◦C. The water
was changed between every animal. The animals were removed
from the water after 6 min, and dried before they returned to
their home cages. Behavior was analyzed in the last 4 min of
the test (Guzzetti et al., 2008). The experiment was recorded and
analyzed automatically using NOLDUS Ethovision XT9 software
(Wageningen, The Netherlands).
Open Field Test
Mice were tested in the OFT for 5 min. The open ﬁeld arena
(46 cm × 46 cm) was illuminated by a reﬂected light of
approximately 35 lux. Performance in the OFT was tracked and
analyzed using an automated video tracking system (NOLDUS
Ethovision XT9, Wageningen, The Netherlands).
Passive Avoidance Test
The step-through passive avoidance (PA) was performed as
described earlier (Eriksson et al., 2013). Brieﬂy, the PA apparatus
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(25 cm × 50 cm × 25 cm) consisted of two equally sized
compartments connected by a sliding door (7 cm × 7cm)
(Ugo Basile, Comerio-Varese, Italy). The light intensities in
the dark and the bright compartments were 2 and 250 lx,
respectively. During PA training, each mouse was placed in the
bright compartment and allowed to explore it for 60 s. The
sliding door was then opened and the animal had a maximum
of 300 s to step through to the dark compartment. Once the
mouse had entered the dark compartment, the sliding door was
automatically closed and, after 3 s, a weak electrical stimulus
(0.3 mA, 2 s scrambled current) was delivered through the grid
ﬂoor.
After 1 h short term memory (STM) or 24 h long term
memory (LTM), the animal was again gently placed in the light
compartment, and the latency to enter the dark compartment
with all four paws was measured (retention latency) with
a 9 min cutoﬀ time for testing. No electrical stimulus was
given during the second exposure. The parameters evaluated
were retention latency, grooming, and rearing. All parameters
were observed and registered manually during the experiment
(latency to step through, grooming and rearing). The animals
were euthanized 1 h after the test and their brains were
later used for the in situ hybridization (described in Section
“Immunoblotting”).
Elevated Plus-Maze
The elevated plus-maze (EPM) was conducted as previously
described (Kindlundh-Högberg et al., 2009). Mice were placed
in the center facing an open arm and allowed to explore the
apparatus for 5 min. Entries into the open (90 lux) and closed
(20 lux) arms and time spent in each arm were measured by
automated video tracking system (NOLDUS Ethovision XT9,
Wageningen, The Netherlands). The animals were euthanized
1 h after the test and their brains were later used for the




Mice were sacriﬁced by decapitation; their brains were quickly
dissected and dipped in isopentane, cooled in dry ice, for
approximately 5 s. Samples were stored in −80◦C freezer for
further processing.
In Situ Hybridization
Fresh frozen coronal cryostat sections (14 μm) were prepared
and hybridized with 35S-radiolabeled antisense riboprobes
against Arc and c-fos. The sections were exposed to Kodak
MR ﬁlm in room temperature for 7–21 days prior to
development, according to a previously published protocol
(Svenningsson et al., 1998, 2006). The areas selected for
analysis were the PFC, the striatum/CPu, the nucleus accumbens
(NAcc), the amygdala (basolateral nuclei of amygdala –
LA/BLA), and the hippocampus (Hi – four diﬀerent subareas:
Cornu Ammonis – subareas CA1, CA2, CA3, and dentate
gyrus – DG). Densitometric measurements were obtained
from autoradiograms using the NIH ImageJ 1.40 software
(National institute of Mental Health, Bethesda, MD, USA).
All optical density values were normalized. For each target
analyzed, the average of the control group (naïve group
treated with saline) was normalized to 100% and results from
each treatment group are presented as percentage of the
control.
Immunoblotting
Tissues from PFC, hippocampus, and caudate-putamen (CPu)
were sonicated and boiled in 1% sodium dodecyl sulfate
(SDS) containing a protease and phosphatase inhibitor Cocktail
(HaltTM, Pierce, Rockford, IL, USA). Protein concentration was
determined in each sample using a bicinchoninic acid protein
assay (BCA-kit, Pierce, Rockford, IL, USA). Equal amounts
of protein (5–20 μg) were separated by SDS–polyacrylamide
gel electrophoresis using 8% lower running gels. Proteins
were transferred to Immobilon-P (Polyvinylidene Diﬂuoride)
membranes (Millipore, Bedford, MA, USA). Membranes were
blocked by incubation in 5% (w/v) dry milk or bovine
serum albumin (BSA) in TBS-Tween20 for 1 h at room
temperature. Following overnight incubation with primary
antibodies (Table 1), the membranes were washed three times
with TBS-Tween 20 and incubated for 1 h with secondary
horseradish peroxidase (HRP)-linked Anti-Rabbit IgG (H + L)
(Dako, Glostrup, Denmark). Immunoreactive bands were
detected by enhanced chemiluminescence (Bio-Rad, Bio-Rad,
Hercules, CA, USA) and quantiﬁed by densitometry with ImageJ
1.40 software. All data are presented as values normalized to the
levels of β-actin or calnexin. The level of the phosphorylated
form of a protein was normalized to the total level of the
same protein. For each target analyzed, the average of the
saline group was normalized to 100% and results from each
treatment group are presented as percentage of the saline
group.
Statistical Analysis
Data were initially evaluated for outliers with the Grubb’s test.
Immunoblotting and behavior in the PA test and were analyzed
with Student’s t-test. Dose-response eﬀects of WAY208466 on
the OFT and FST were analyzed by one-way analysis of variance
(ANOVA) with treatment as a factor. Arc and c-fos expression
were analyzed with two-way ANOVA with training × treatment
TABLE 1 | List of the antibodies and dilutions used for the immunoblotting.
Antibody Company Catalog number Dilution
Actin Sigma A5060 1:10000
Calnexin Sigma C4731 1:2000
Glu R1 Milipore 06–306 1:1000
P-Ser845 Glu R1 Milipore 04–823 1:1000
MEK Cell signaling 9122 1:1000
P-Ser217/221 MEK Cell signaling 9121 1:1000
Erk1/2 Cell signaling 9107S 1:2000
P-Thr202/204 Erk1/2 Cell signaling 9101S 1:1000
proBDNF Alomone ANT-006 1:200
mBDNF Sigma AV-41970 1 μg/ml
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as factors. ANOVAs were followed by Fisher’s least signiﬁcance
diﬀerence (LSD) post hoc test. All data are presented as




Analysis with one-way ANOVA showed a statistical diﬀerence
between treatments (F3,28 = 3.045; p < 0.05). Fisher post hoc
analysis showed that 9 mg/kg of WAY208466 decreased the
immobility (Figure 1A).
Open Field Test
One-way ANOVA showed a statistical diﬀerence between
treatments (F3,28 = 6.70, p < 0.01). WAY208466, at the highest
dose (27 mg/kg), decreased locomotion (Figure 1B).
Passive Avoidance Test
No signiﬁcant diﬀerences were observed between the saline
group andWAY208466 (9 mg/kg) during the training session for
either short term or long term memories in the latency to step
through to the dark compartment (t = −1.44, p< 0.17; t = 0.29,
p < 0.2, respectively). However, during the test section, student
t-test showed a signiﬁcant diﬀerence for both short (t = −2.21,
p < 0.05) and long (t = −2.64, p < 0.01) term memories
(Figure 2).
During the PA test, grooming and rearing were also examined.
No signiﬁcant diﬀerences were observed during training sessions
for either grooming (t = −1.55, p < 0.14; t = −0.17, p < 0.87,
respectively) or rearing (t = 0.40, p < 0.69; t = −0.17, p < 0.87,
respectively). However, rearing was signiﬁcant increased by
WAY208466 (9 mg/kg) both in the test sessions for short and
long term memories (t = −5.22, p < 0.001; t = −3.55, p < 0.01,
respectively). Grooming was increased by WAY208466 in the
STM paradigm (t = −3.97, p< 0.01), but not in LTM (t = −0.36,
p< 0.72) (Figure 3).
FIGURE 1 | Effects of WAY208466 treatment in the forced swim test
(FST) and open field test (OFT). (A) Immobility duration in the FST showing
antidepressant-like effect of WAY208466 after 9 mg/kg (ip). (B) Total distance
moved during 5 min in the OFT. WAY208466 at 27 mg/kg (ip) caused motor
impairment compared to the saline group. ∗p < 0.05 compared to saline
group, ¤p < 0.05 compared to 27 mg/kg. ++p < 0.01 compared to 9 mg/kg
WAY208466 group. Mean ± SEM; n = 8 mice per group.
FIGURE 2 | Retention latency in the PA test. Animals were treated with
saline or WAY208466 (9 mg/kg), 30 min prior test (ip). (A) Short term (1 h)
memory (STM) comparison between treatments. (B) Long term (24 h) memory
(LTM) comparison between treatments. ∗∗p < 0.01 compared to saline group.
Mean ± SEM, n = 8 mice per group.
FIGURE 3 | Rearing (A,B) and grooming (C,D) during PA test. Differences
in the number of rearings between treatments [saline or WAY208466
(9 mg/kg)] for STM (A) or LTM (B). Differences in the frequency of groomings
between treatments [saline or WAY208466 (9 mg/kg)] for STM (C) or LTM (D).
∗∗p < 0.01; ∗∗∗p < 0.001 compared to saline group. STM, short term
memory; LTM, long term memory. Mean ± SEM; n = 8 mice per group.
Elevated Plus-Maze
No signiﬁcant diﬀerences were observed between the saline
group andWAY208466 (9mg/kg) in the EPM test. Student’s t-test
showed no diﬀerences in neither number of entries in the open
arm of the maze (t = 1.59, p < 0.13), nor in time spent in the
open arm (t = 1.66, p< 0.11) (Table 2).
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TABLE 2 | Effects of saline and WAY208466 (9 mg/kg) treatment in the
EPM test.
Treatment Entries in the open arms Time (sec) spent in the
open arms
Saline 18.6 ± 0.92 117.5 ± 12.8
WAY208466 17.0 ± 1.10 99.11 ± 8.97




No signiﬁcant changes in c-fos or Arc expression were observed
in any of the analyzed areas (PFC, CPu, NAccs, amygdala,
and hippocampus) in animals studied in the STM paradigm
of PA.
However, in the LTM PA paradigm, two-way ANOVAs
followed by Fisher’s post hoc test showed increases of both
hippocampal c-fos and Arc mRNAs in tested animals treated
with WAY208466 in comparison with either saline/trained
(p < 0.05 and p < 0.01, respectively) or treated/naïve
(p < 0.05, p < 0.01, respectively) groups. (c-fos: treatment:
F1,21 = 1.88, p < 0.05, training F1,21 = 2.08, p > 0.05,
treatment × training interaction: F1,21 = 5.26, p < 0.05; Arc:
treatment: F1,21 = 5.67, p < 0.05, training: F1,21 = 11.10,
p< 0.01, treatment× training interaction: F1,21 = 4.82, p< 0.05)
(Figures 4E and 5E).
A two-way ANOVA also detected a treatment eﬀect of
WAY208466 in the Arc expression in the PFC in the
LTM paradigm (treatment: F1,21 = 4.75, p < 0.05, training:
F1,21 = 2.56, p > 0.05, treatment × training interaction:
F1,21 = 0.12, p > 0.05). Speciﬁcally, WAY208466 treatment
prevented the reduction in Arc expression observed in trained
animals in comparison with the naïve groups (p < 0.05)
(Figure 5A).
No signiﬁcant changes were observed for the other analyzed
areas in the long term memory paradigm (Figures 4A–D and
5B–D).
Western Blot
Acute treatment with WAY208466 (9 mg/kg) increased the levels
of phospho-Ser845-GluA1 in the CPu (t = 2.21, p< 0.05), but not
in the PFC or hippocampus (t = 0.88, p > 0.2; t = 0.35, p > 0.2,
respectively) (Figure 6C). Similarly, phospho-Ser217/221MEKwas
also increased in the CPu (t = 2.31, p< 0.05), but not in the PFC
or hippocampus (t = 1.03, p> 0.2; t = 0.68, p> 0.2, respectively)
(Figure 6A).
Levels of phospho-Thr202/204Erk1/2 were increased in the
hippocampus (t = 2.71, p < 0.05), but not in the PFC or CPu
(t = 0.33, p > 0.2; t = 0.10, p > 0.2, respectively) (Figure 6B).
Likewise, the ratio of mature BDNF/proBDNF was increased in
the hippocampus (t = 2.71, p< 0.05), but not in the PFC or CPu
(t = 0.95, p> 0.2, respectively) (Figure 6D).
Discussion
Our results show that the 5-HT6 agonist WAY208466 facilitates
cognitive processing in the PA test and has an antidepressant-like
eﬀect in the FST. In agreement with a previous study performed
in rats (Carr et al., 2011), we observed a U-shape dose-response
curve in the antidepressant eﬀect of WAY208466. The study of
Carr et al. (2011) used rats as they have higher expression of 5-
HT6 receptors when compared to mice (Hirst et al., 2003; Zhang
et al., 2011). Nonetheless, our data demonstrates antidepressant
properties of WAY208466 also in mice.
In addition of improving the performance in the PA test,
WAY208466 also increased grooming and rearing during this
test. Grooming/rearing in a new environment interacts with
anxiety in a complex manner (Prut and Belzung, 2003).
Furthermore, since Carr et al. (2011) found an anxiolytic-like
FIGURE 4 | Effects of saline and WAY208466 (9 mg/kg, ip) on the levels of c-fos mRNA after PA test for STM (upper) or LTM (lower) for (A) PFC, pre
frontal cortex; (B) BA/BLA, lateral and basolateral amygdala; (C) CPu, caudate putamen; (D) NAcc, nucleus accumbens; (E) Hi, hippocampus.
∗p < 0.05 compared to saline/naïve group. ¤p < 0.05; ¤¤p < 0.01 compared to saline group. Mean ± SEM; n = 6–8 mice per group.
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FIGURE 5 | Effects of saline and WAY208466 (9 mg/kg, ip) on the levels of Arc (activity-regulated cytoskeleton-associated protein) mRNA after PA
test for STM (upper) or LTM (lower) for (A) PFC, pre frontal cortex; (B) BA/BLA, lateral and basolateral amygdala; (C) CPu, caudate putamen;
(D) NAcc, nucleus accumbens; (E) Hi, hippocampus. ∗p < 0.05; ∗∗p < 0.01 compared to saline naïve group. ¤¤p < 0.01 compared to saline group.
Mean ± SEM; n = 6–8 mice per group.
FIGURE 6 | Effects of saline or WAY208466 (9 mg/kg, ip) on the phosphorylation states of Ser217/221-MEK (A), Thr202/204-Erk1/2 (B), Ser845-GluA1 (C)
and the ratio matureBDNF/proBDNF (D) in the prefrontal cortex (PFC), hippocampus, and caudate-putamen (CPu). ∗p < 0.05; ∗∗p < 0.01 compared to
saline group. Mean ± SEM; n = 6–8 mice per group.
eﬀect of WAY208466, we performed experiments in EPM.
Somewhat surprisingly, we did not ﬁnd a signiﬁcant eﬀect of
WAY208466 in the EPM. It is important to note that the absence
of eﬀect in our experiment might be related to the low sensitive
of the EPM test to serotoninergic drugs.
The OFT was performed to evaluate for possible locomotor
eﬀects induced by WAY208466 that could bias the subsequent
behavioral tests. We found that 27mg/kg ofWAY208466 reduced
locomotion in the OFT. This result is inconsistent with a previous
report (Carr et al., 2011), in which 30 mg/kg of WAY208466
caused no hypolocomotion in rats. The discrepancy between
these results may, at least partly, be explained by diﬀerent
experimental designs. Carr et al. (2011) treated rats for 1 h
before examining their locomotion for 30 min, whereas we
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treated mice for 30 min before examining their locomotion
for 5 min. A possible explanation for the diﬀerent results
is that our experiments are strongly inﬂuenced by a novelty
response together with regular locomotor activity, whereas
the results from Carr et al. (2011) were less inﬂuenced
by novelty. Based on this result in the OFT we decided
to not perform additional experiment with 27 mg/kg of
WAY208466. 3 and 9 mg/kg of WAY208466 caused no
hypolocomotion, but only 9 mg/kg decreased immobility in
the FST. Based on these results, the subsequent EPM and
PA experiments were only performed using 9 mg/kg of
WAY208466.
To better understand the molecular mechanisms and brain
regions involved in the facilitation of emotional learning
by WAY208466, we correlated its behavioral eﬀects with
alterations on signal transduction and IEG expression. Studies
have reported the importance of mitogen-activated protein
kinase (MAPK) signaling pathway in the process of memory
consolidation (Thomas and Huganir, 2004). We observed that
WAY208466 increased the phosphorylation of MEK in the
CPu and Erk1/2 in the hippocampus. Interestingly, treatment
with the clinically used procognitive agent, memantine, has
also been shown to both improve the PA performance and
to increase hippocampal Erk1/2 phosphorylation (Liu et al.,
2014).
Corroborating with our previous results using EMDT
(Svenningsson et al., 2007), treatment with WAY208466
increased phosphorylation of the Ser845-GluA1 receptors in the
CPu. Phosphorylation of Ser845-GluA1 in the ventral striatum has
been reported to be important for spatial memory consolidation
(Ferretti et al., 2014). The role of the CPu for learning the
PA task is not as evident as that of hippocampus, although
cholinergic blockade in the CPu impairs the memory formation
in the PA test (Prado-Alcalá et al., 1985). Unlike our previous
report with EMDT, (Svenningsson et al., 2007) WAY208466
treatment did not increase Ser845-GluA1 phosphorylation in the
PFC.
BDNF is critically important in multiple plastic changes
regulating mood and cognition and was therefore also
studied in the immunoblotting experiments. Treatment with
WAY208466 did not change mature BDNF or proBDNF levels
in hippocampus. However, the ratio of mature BDNF/proBDNF
was increased, favoring neuronal plasticity.
To determine brain regions aﬀected by the PA paradigm
and 5-HT6 agonism, we evaluated the expression of the IEGs
Arc and c-fos by in situ hybridization. Since the initial increase
of c-fos and Arc after a neuronal stimuli can occur already
after 15 min and last for many hours (Katche et al., 2010;
McReynolds et al., 2010), we studied both short (1 h) and
long (24 h) term PA paradigms. No changes in expression
of these genes were found in response to the short term
paradigm. However, the long term paradigm decreased Arc
expression in the PFC and increase c-fos expression in the
CPu. Interestingly, both these changes were counteracted by
treatment with WAY208466. The long term paradigm of PA
by itself had no eﬀects on Arc and c-fos in hippocampus, but
WAY208466 caused a signiﬁcant increase of both these genes
in this region. Our data is in agreement with previous data
showing increased hippocampal and cortical Arc expression
in animals treated with another 5-HT6 agonist, LY586713
(de Foubert et al., 2007). The 5-HT6 receptor is, indeed,
coupled to Gαs proteins, which stimulate adenylate cyclase and
downstream signaling mechanisms (Yun et al., 2007; Riccioni
et al., 2011). It is therefore possible that some of the IEG
activation seen here is a direct action of 5-HT6 agonism on
hippocampal and cortical neurons. However, since these brain
regions express relatively low levels of 5-HT6 receptors, it is
also likely that these Arc and c-fos responses reﬂect indirect
activation. There are dense projections from the midbrain to the
PFC and hippocampus (Ongür and Price, 2000) and there are
multisynaptic loops interconnecting ventral striatum, where 5-
HT6 receptors are very high, with the PFC and hippocampus.
Because both 5-HT6 agonists and antagonists are procognitive
in several memory tasks, it would be interesting to compare
their eﬀects on IEG expression. To our knowledge, there are no
publications describing IEG expression after treatment with a
5-HT6 antagonist.
Conclusion
WAY208466 facilitated emotional learning and induced
antidepressant-like, but not anxiolytic, actions. Moreover,
this 5-HT6 agonist stimulated molecular changes relevant
for neuronal plasticity and memory formation in CPu, PFC
and hippocampus. As noted above, the associations between
behavioral responses and the molecular markers reported
here are strictly correlational. To establish a causal relation
between these events, experiments using gene knockouts
would be necessary. Nonetheless, these data further emphasize
an important role of 5-HT6 receptors in the regulation
of neuronal signal transduction in relation to mood and
cognition.
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